Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top London based President operating in the Health Care space. If you think a President is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Arjun Purkayastha
Senior Vice President – eCommerce, Digital & Ventures of Reckitt
Arjun Purkayastha is a purpose driven leader with extensive global experience managing diverse businesses and multi-cultural teams at FTSE Top 10 and Fortune 100 companies – RB and P&G. He has a strong track record of building outperforming teams, iconic brands & innovative business models across 60+ countries having lived & worked in the UK, Singapore, South Korea and India. He currently leads eCommerce, CRM, digital, DNVB & start up ventures globally for RB with P&L, strategic and operational responsibility of all online channels & customers. He serves on the Board of Directors of 4 high growth, online focused companies – Pharmapacks.com (one of the largest and best 3P resellers on Amazon), Bombay Shaving Company (leading men’s wellness company in India), UpSpring (mom & baby products) and Healthily by Your.MD (AI powered self care). He is also an Investment Committee Member of Founders Factory & RB’s JV focused on Hygiene & Home start ups.
Follow Arjun Purkayastha:
About Reckitt: Reckitt Benckiser Group is a consumer goods company makes health, hygiene and home products.
Shaun Grady
Vice-President Business Development Operations of AstraZeneca
Shaun Grady has responsibility for Global Business Development at AstraZeneca, leading the company’s transaction execution, due diligence and Alliance and Integration Management function including externalisation, licensing and partnering, M&A, and divestments. Shaun was appointed to his current role in 2013 with the creation of the Global Product and Portfolio Strategy (GPPS) unit. Prior to this, he was Vice President, Strategic Partnering & Business Development (2010-13) and Vice President, Corporate Business Development (2006-10). Shaun originally joined ICI as an attorney and held positions in the pharmaceuticals, petrochemicals, and legal departments. Following the demerger from ICI, he was appointed Assistant General Counsel, Corporate for Zeneca. Shaun worked on the merger of Astra and Zeneca, the merger of Zeneca Agrochemicals with Novartis Agribusiness to form Syngenta, and the creation of Avecia. Shaun also worked on the acquisition of Cambridge Antibody Technology (CAT), led the acquisition of Amylin, and subsequent buy-out of Bristol-Myers’ Squibb’s interest in the AZ-BMS Diabetes Alliance. In addition, he has spent time in the US business managing the legal function and also completed a two year secondment to HR, leading a global People Strategy change project. Shaun is an Honorary Fellow in Entrepreneurship at Cambridge Judge Business School and is a member of the Board of Cambridge United Football Club and Cambridge Arts Theatre. Based in Cambridge, Shaun enjoys rugby and football, and occasionally turns his hand to sports writing.
Follow Shaun Grady:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Steve Cahillane
President & Chief Executive Officer of NBTY
Steve Cahillane joined NBTY in September 2014 as President & CEO. Since that time, he has also served as a member of the Board of Directors of NBTY. Prior to joining NBTY, Steve served as President of Coca-Cola Americas, which consists of both the North American and Latin American operations. Before assuming that role, he held positions as President and CEO of Coca-Cola Refreshments (CCR), an operating unit of the North American business of The Coca Cola Company, and President of Coca-Cola Enterprise’s (CCE) North American business. Mr. Steven A. Cahillane, also known as Steve, has been the Chief Executive Officer and President at Kellogg Company since October 2, 2017 and has been its Chairman since March 16, 2018. Mr. Cahillane possesses particular knowledge and experience in a variety of areas, including accounting and financial acumen, risk management, innovation and research and development, branded consumer products and consumer dynamics, regulatory and government that strengthens the Board’s
Follow Steve Cahillane:
About Kellogg’s, NBTY: NBTY is a leading global vertically integrated manufacturer, marketer and distributor.
Jeanne Bolger
Vice President Venture Investing of Johnson & Johnson Development Corporation
Jeanne Bolger, MB BCh BAO, Vice President, Venture Investments, joined Johnson & Johnson Development Corporation (JJDC) in 2013. She is based in London, UK. Dr. Bolger has over 25 years of pharmaceutical industry experience in management roles across R&D, Commercial and Business Development (BD). She spent 11 years in Licensing and Acquisition (L&A), most recently as Global Head of Scientific Licensing for Johnson & Johnson’s Pharmaceutical business, having joined Johnson & Johnson in 2005 from the Business Development group at GlaxoSmithKline. In 2009, Dr. Bolger became Vice President, Alliance Management at Janssen Alzheimer Immunotherapy, working with Pfizer and Elan. Dr. Bolger received her medical degree from University College Dublin. She also holds diplomas in Child Health (NUI) and in Finance and Accounting (ACCA). She is a Fellow of the Royal Academy of Medicine of Ireland (RAMI). Dr. Bolger has served as the sole pharma industry representative on two Irish government taskforces seeking to enhance the commercialization of IP from Irish academic centres. She is a visiting lecturer on the MSc Pharmaceutical Medicine curriculum at Trinity College in Dublin, Ireland.
Follow Jeanne Bolger:
About Johnson & Johnson Development Corporation, Pulmocide: Johnson & Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Michael Gibbs
Co-founder & President of Second Nature
Cambridge pharmacology graduate, strategy consultant, entrepreneur, author, health and nutrition geek. Incredibly strong believer in immersing yourself in the details of science and physiology – rather than the face value of published scientific papers – in order to come to a critical viewpoint on nutrition and public health. “It is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgement of trusted physicians or authoritative medical guidelines” – Marcia Angell, long-time editor of the New England Journal of Medicine.
Follow Michael Gibbs:
About Second Nature: Second Nature is a digital programme that helps people lead healthier lives
Mustapha Rashid
President of British Orthopaedic Trainees Association
Follow Mustapha Rashid:
About British Orthopaedic Trainees Association: Supporting the orthopaedic trainees of today, for the patients of tomorrow
Disa Sanstorn
Senior Vice President Business Development Europe of YgEia3
Follow Disa Sanstorn:
About YgEia3: YgEia3 works with corporations developing comprehensive wellness testing for each company.
Pablo Graiver
President and Founder of Antidote.me
Pablo Graiver is Co-Founder of Antidote Technologies Ltd. (a/k/a TrialReach Ltd.) and serves as its Chief Executive Officer and Executive Director. Pablo Graiver served as Vice President of Business Development, Europe of Kayak Software Corporation. He has over 12 years of entrepreneurial and management experience in the online industry. He was an early member of NetJuice, one of the largest Internet incubators in Europe; MD at Donde Comprar.com, the first e-commerce directory in Spanish; and later co-founder and Vice President of Strategy at Kelkoo, acquired by Yahoo! in 2004. Pablo Graiver set up and launched Kayak.com in Europe, and served as European Sales Director at ValueClick (NASDAQ: VCLK). He studied Biology and Business Administration at UAM in Madrid.
Follow Pablo Graiver:
About Antidote.me: Antidote is a digital health company that accelerates and improves medical research by combining technologies, data, and business models.
Olivier de Beauminy
President of Medylink
Follow Olivier de Beauminy:
About Medylink: Medylink has designs and develops a digital platform that allows general practitioners to coordinate their actions with specialists.
Simon Viggers
Vice President Human Resources of Otsuka Pharmaceuticals
Simon Thule Viggers is a Senior HR Leader with deep global experience. Almost 20 years of experience within Pharma, 15 years in leadership roles across three continents. Proven ability to lead through challenging change and with an ability to approach business in a holistic way. Simon takes the starting point in the business agenda and translates that into actions for the organization and the people. Simon has a strong leadership background as he has been part of executive teams for more than a decade and has been preferred coach to many executives.
Follow Simon Viggers:
About Otsuka Pharmaceuticals: Otsuka Pharmaceuticals is a pharmaceutical company that operates throughout the globe.
Joanna Holbrook
Senior Vice President of Research of Cambridge Epigenetix
Joanna started her career in GSK R&D, working for seven years in the UK bioinformatics department, processing the integrating ‘omic data for drug target identification and validation mostly focussing on neurological disease, and then for three years in GSK USA Oncology R&D working on biomarkers for targeted therapies. She then left GSK and the USA for Singapore and built an academic group in A*STAR Singapore Institute for Clinical Sciences. Her group focused on epigenomic trackers of complex disease, especially the interaction of genetic, environmental and disease states in shaping the human epigenome. Her work in Singapore encompassed set-up of observational and interventional cohorts, biobanking, clinical databases, production, processing and analysis of biosample ‘omic profiles and multiple industrial collaborations. Moving back to the UK five years later, she took up a professorship at the University of Southampton, still working on epigenomics and also integration of electronic health record data to clinical cohorts. Most recently she has been VP of Translational Medicine at BenevolentAI, a fast growing British Biotech, where she initiated and led integration of ‘omic data into a large biomedical knowledge graph and machine learning approaches to analyses of patient-level data for precision medicine.
Follow Joanna Holbrook:
About Cambridge Epigenetix: Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.
Philip M. Toleikis
President & CEO of Sernova
Dr. Toleikis is President and Chief Executive Officer of Sernova Corp since April 2009. From 2006 until 2009, Dr. Toleikis consulted for multiple device, combination product and pharmaceutical companies. From 1996 to 2006 he held multiple roles at Angiotech Pharmaceuticals, Inc. including Vice President, Research and Development – Pharmacology and Drug Screening where he built a product development team of over 50 scientists and was responsible for multiple corporate and academic product development collaborations. While at Sernova, Dr. Toleikis has secured over $60 million in various forms of financings, including equity raises and multiple non-dilutive grants and has been responsible for negotiating a worldwide exclusive license with UHN and University of Miami for its stem cell derived technologies as well as developing business relationships and or collaborations with multiple pharmaceutical and academic institutions involving its Cell Pouch™ device and cell technologies. Dr. Toleikis is an author of over 100 patent applications ande issued patents, and multiple scientific publications involving transplantation, metabolic, cardiovascular, oncology, and autoimmune disease. He obtained his Ph.D. in Medicine, Pharmacology and Therapeutics from the University of British Columbia, his M.Sc. at the University of Michigan and B.A. at the University of Vermont.
Follow Philip M. Toleikis:
About Sernova: Sernova develops regenerative medicine therapeutic technologies for treatment of chronic metabolic diseases.
Clare Cooper
Founder and Vice President of Storm3
Clare Cooper is the Founder and Vice President at Storm3.
Follow Clare Cooper:
About Storm3: Storm3 are a global HealthTech talent marketplace, connecting organizations with the talent to drive their mission.
William Richardson
Executive Vice President of Savaria Corp
Follow William Richardson:
About Savaria Corp: Savaria provides accessibility solutions for the elderly and physically challenged to increase their mobility and independence.
Richard Lagani
Executive Vice President of MMRGlobal
Richard Lagani is an Senior Management Professional
Follow Richard Lagani:
About MMRGlobal, MMRGlobal: MMRGlobal provides secure, easy-to-use multilingual personal health records (PHRs) and electronic safe deposit box storage solutions.
Debasish Talukdar
President, Global Head of Advisory of Prescient Healthcare Group
Follow Debasish Talukdar:
About Prescient Healthcare Group: Prescient Healthcare Group was founded in London in 1995, originally specializing in competitive insights.
Bryan Olin
Senior Vice President of LivaNova
Bryan Olin, PhD is the Senior Vice President, Clinical, Quality & Regulatory Affairs at LivaNova. Dr. Olin joined Cyberonics in May 2009 as Vice President, Quality. In August 2009, he assumed additional responsibility for Clinical Affairs, and in April 2011, his responsibilities were expanded again to include Regulatory Affairs. With the 2015 merger between Cyberonics and Sorin, his responsibilities expanded to include corporate-wide responsibilities for the clinical, quality and regulatory affairs functions at LivaNova. Prior to May 2009, Dr. Olin was employed at Zeltiq Aesthetics, Inc., a privately held medical technology company in the San Francisco area, where he served as Sr. Director, Quality Assurance since October 2007. Prior to Zeltiq Aesthetics, Dr. Olin was employed at the LifeScan and Cordis companies of Johnson & Johnson from 1999 to 2007, holding several positions of increasing responsibility in quality assurance, statistics and clinical data management. Dr. Olin began his career with Procter & Gamble in 1993 after obtaining his Ph.D. in Statistics from Iowa State University. He currently serves on the board of directors for the Medical Devices Innovation Consortium (MDIC) and as an industry representative on the Advisory Committee for The National Patient-Centered Clinical Research Network (PCORnet).
Follow Bryan Olin:
About LivaNova: LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment.
Jim Knight
President of xRapid
Follow Jim Knight:
About xRapid: xRapid is a mobile health diagnosis through disruptive solutions leveraging the use of artificial intelligence.
Kris Famm
President of Galvani Bioelectronics
Molecular biologist turned bioelectrician, Kris Famm leads Galvani Bioelectronics, a partnership between GSK and Alphabet to develop implantable medical devices.
Follow Kris Famm:
About Galvani Bioelectronics: Galvani Bioelectronics is developing ways to treat chronic illnesses by controlling electrical impulses in the body.
Maria Karam
Founder, President of Tactile Audio Displays Inc.
Follow Maria Karam:
About Tactile Audio Displays Inc.: R&D Leaders in Sound Systems for the body
Raymond Hill
President of Emeritus of British Pharmacological Society
Prof. Raymond Hill currently holds several board seats and professorships. He also serves as President Emeritus of the British Pharmacological Society, as a co-opted member of Council, Academy of Medical Sciences and sits on the Advisory Council on Misuse of Drugs. Dr Hill was Executive Director, Licensing and External Research, Europe for Merck, Sharp and Dohme (MSD). He additionally had oversight responsibility for Neuroscience research at the MSD / Banyu Research Labs in Tsukuba, Japan. At MSD he chaired discovery project teams responsible for currently marketed products Maxalt and Emend. Dr Hill is a non-executive director of Avilex, Covagen and Orexo. He is visiting professor at Imperial College in London, and the University of Bristol. Dr Hill received BPharm and PhD degrees from the University of London and was elected to Fellowship of the Academy of Medical Sciences in 2005.
Follow Raymond Hill:
About British Pharmacological Society, Covagen, Orexo: Formed in 1931 the BPS, including its Clinical Pharmacology Section, is the professional association for pharmacologists in the UK
Nicholas Lakin
Vice President, Advisory Services of Kinapse
Follow Nicholas Lakin:
About Kinapse: Kinapse provides advisory, capability building and operational services to the life sciences industries.
